European Union - Latvian - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - quizartinib dihydrochloride - leikēmija, mieloīds - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.

Latvia - Latvian - Zāļu valsts aģentūra

kalceks, a/s, latvia - kalcija folināts - Šķīdums injekcijām/infūzijām - 10 mg/ml